Promising Data on Vertex T1D Islet Cell Study, Still Recruiting

Vertex Pharmaceuticals is conducting a clinical trial to evaluate the safety, tolerability, and effectiveness of an investigational islet cell infusion called VX-880 in adults with type 1 diabetes who have a history of severe low blood sugar and impaired hypoglycemic awareness.

The trial involves infusing manufactured insulin-producing beta cells along with immunosuppression therapy with the aim of protecting the beta cells from the T1D autoimmune attack, and providing replacement cells for the ones that have been lost or don’t work properly.

Participants must have a clinical history of type 1 diabetes with onset occurring before age 40, and they must be insulin dependent for five years or more. They must also meet the following key criteria:

• Male or female between the ages of 18 and 65
• Severe hypoglycemia, meaning you have required assistance from somebody else to recover from low blood sugar
• Blood type of A or AB
• Do not have significant active infection or chronic infection such as hepatitis B or C, HIV, tuberculosis, invasive aspergillus, histoplasmosis, or coccidioidomycosis within the past year
• Do not have advanced complications associated with diabetes including untreated proliferative retinopathy, skin ulcers, or amputations attributable to diabetes
• Consistent use of a continuous glucose monitor (CGM) for the last three months

There are additional eligibility requirements, which the study doctor can explain. If you’re interested in being part of the study, visit www.T1Dstudy.com for more information and to apply.